Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

By R. Laheij, M. Sturkenboom, R. Hassing, J. Dieleman, B. Stricker, J. Jansen. Journal of the American Medical Association (JAMA), 2004

898 citations recorded by the source corpus.

Subfields: Critical Care and Intensive Care Medicine, Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/a5ff6c26c64b11f9a8b7c1fc2d1b1616661bc707

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Hassall
2. G. Veereman‐Wauters
3. J. Marshall
4. A. Staiano
5. J. Leonard
6. C. Rudolph
7. T. Wenzl
8. P. Moayyedi

Citations in the corpus

• Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression (2007, background): “Concerns over the more serious side effects such as community-acquired pneumonia have also been raised but their biologic plausibility is uncertain (3).”
• Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) (2009, background): “The potential benefits of antisecretory therapy for neurologically impaired children with recurrent pneumonia must be balanced against the risk that PPI therapy may increase the incidence of community-acquired pneumonia in these patients, as it does in well children (322).”